Rallidae Therapeutics
- Biotech or pharma, therapeutic R&D
Rallidae Therapeutics is developing a clinically validated therapeutic peptide approach to complications of cirrhotic liver disease including refractory ascites, a condition with high mortality and few therapeutic options today. The Rallidae team and approach has been validated by extensive translational pharmacology and Phase 2 clinical data showing safety and efficacy, with a clear path to discover and develop a best in class NCE for a $1B market, producing a meaningful step forward for patients. We are currently raising a seed round to discover and validate a clinical candidate for refractory ascites and related complications of cirrhotic liver disease.
Address
CaliforniaUnited States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}